Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Iovance Biotherapeutics (IOVA) Asset Writedowns and Impairment (2024 - 2025)

Iovance Biotherapeutics (IOVA) has disclosed Asset Writedowns and Impairment for 3 consecutive years, with $3.7 million as the latest value for Q4 2025.

  • On a quarterly basis, Asset Writedowns and Impairment fell 49.64% to $3.7 million in Q4 2025 year-over-year; TTM through Dec 2025 was $12.5 million, a 69.39% increase, with the full-year FY2025 number at $13.4 million, up 82.24% from a year prior.
  • Asset Writedowns and Impairment was $3.7 million for Q4 2025 at Iovance Biotherapeutics, up from $1.4 million in the prior quarter.
  • In the past five years, Asset Writedowns and Impairment ranged from a high of $7.4 million in Q4 2024 to a low of $1.4 million in Q3 2025.